COMMUNIQUÉS West-GlobeNewswire

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
11/02/2026
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma [...]
Psyence BioMed Announces Settlement of Shareholder Litigation
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a direct shareholder [...]
Coloplast A/S - Updated Financial Calendar 2025-26
11/02/2026
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The [...]
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
11/02/2026
A Global Leader in Breast Imaging and AI, Dr. Lehman is Advancing AI-Driven Risk Assessment to Identify Women at Elevated Risk Years Before Diagnosis TIME’s Annual List Recognizes 100 of the World’s Most Influential [...]
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
11/02/2026
BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market [...]
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
11/02/2026
• First MYC condensate-modulating small molecule advanced to Development Candidate • Demonstrates potent, selective inhibition of MYC-driven transcription via condensate modulation • Preclinical data support potential [...]
DIL Walk Foundation Takes National and Global Leadership Role in Advancing Precision Health and Healthspan
11/02/2026
CALGARY, Alberta, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The DIL Walk Foundation is strengthening its leadership role in advancing precision health, longevity research, and healthspan-focused care, positioning Canada as an [...]
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
PL BioScience Wins Regulatory Certification from Japan’s PMDA
11/02/2026
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has issued a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (GMP Grade) cell culture media. The PMDA Certification is the first regulatory [...]
NTG Nordic Transport Group A/S - 2025 Annual Report Conference Call
11/02/2026
NTG Nordic Transport Group A/S – 2025 Annual Report Conference Call We expect to release the 2025 Annual Report of NTG Nordic Transport Group on the evening of March 4, 2026. A webcast and conference call will be held [...]
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026
DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces expanded leadership roles [...]
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]

Pages